ADFE application may downregulate the immune pathogenesis implicated with TH2 predominance in acute AD phase, which could be supported by the present results with lowered ratios of IL-4/IFN-γ and IgG1/IgG2a in the acute phase. The gene discussed is IL4; the disease is Alzheimer disease.